# Which choice fits the soreness and your daily life? *Biologic Injections Mesa | Care Options and Tradeoffs* > Biologic injections Mesa choices explained through home care, blood or marrow procedures, gel shots and surgery alternatives. Does lasting soreness mean you need a procedure? Not always. The cause, joint damage, daily limits, cost, and recovery time all matter before you choose. Start with the lowest burden that fits the problem. ## What can help before a procedure? Gentle exercise can keep strength around the sore joint. A physical therapist can teach movements that don't overload it. Warmth may ease stiffness as you get moving, while cold may calm swelling later. Weight loss can reduce pressure when that applies to you. These choices take effort, but they add no procedure risk. Home care can remain useful while you consider other choices. ## How do the main joint procedures differ? A steroid may ease soreness sooner, though its effect may fade. A hyaluronic acid injection uses a thick gel containing a normal part of joint fluid. The gel is meant to act like that fluid. PRP uses a small portion collected after your blood is spun. BMAC uses marrow taken at the pelvis and spun. Each choice brings different cost, aftercare, and sore spots. ## What can QC Kinetix discuss with you? QC Kinetix offers natural pain treatments and regenerative care. The second term means non-surgical procedures using prepared blood or marrow. Licensed clinic staff, called medical providers, can review the exam and your daily goals. They can also discuss concentrated PRP and non-surgical choices for a knee or hip. Don't leave without asking what relief is reasonable and when you could judge it. ## When is a surgical opinion useful? A surgical opinion may help when an X-ray shows severe wear or the joint has changed shape. You remain free to say no after that visit. The exam can show how much damage is present and whether waiting has a cost. Tell the surgeon about recent joint procedures because timing may matter. You can compare surgery with other care after that exam. ## Sources 1. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature Medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study. Whittle SL, et al. — [Stem cell injections for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/40169165/). *Cochrane Database of Systematic Reviews*, 2025. DOI: 10.1002/14651858.CD013342.pub2. 4. In a within-patient placebo-controlled trial, 25 people with BILATERAL knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline in the other, acting as their own controls. Pain scores fell significantly from baseline in BOTH knees at 1 week, 3 months and 6 months, and the relief - described by the authors as dramatic - did not differ significantly between the BMAC knee and the saline knee. Shapiro SA, et al. — [A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/27566242/). *American Journal of Sports Medicine*, 2017. DOI: 10.1177/0363546516662455. 5. The BMJ meta-analysis of viscosupplementation pooled 169 trials (21,163 participants) and found clear evidence of small-study effects and publication bias. In the prespecified main analysis of 24 LARGE placebo-controlled trials (8,997 participants) hyaluronic acid reduced pain by SMD -0.08 (95% CI -0.15 to -0.02), equivalent to 2.0 mm on a 100 mm scale - far below the -0.37 minimal important difference - and trial sequential analysis showed there has been CONCLUSIVE evidence of clinical equivalence to placebo since 2009. Fifteen large trials showed a significantly higher risk of serious adverse events (RR 1.49). Pereira TV, et al. — [Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36333100/). *BMJ*, 2022. DOI: 10.1136/bmj-2022-069722. 6. A multicenter single-blind RCT randomised 200 patients 1:1:1 to a single injection of saline, hyaluronic acid or amniotic suspension allograft. ASA produced significant KOOS and VAS improvements maintained through 12 months with a 63.2% OMERACT-OARSI responder rate, no radiographic differences, and no concerning immunoglobulin or anti-HLA responses. Adverse events with ASA were comparable to HA, while NO treatment-emergent adverse events were reported in the saline group. Gomoll AH, et al. — [Safety and Efficacy of an Amniotic Suspension Allograft Injection Over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee.](https://pubmed.ncbi.nlm.nih.gov/33716121/). *Arthroscopy*, 2021. DOI: 10.1016/j.arthro.2021.02.044. 7. FDA's July 2020 final guidance 'Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use' is the document that decides whether a given orthobiologic can be used without a licence: an HCT/P may be regulated solely under section 361 only if it is minimally manipulated AND intended for homologous use, among other criteria; otherwise it is a drug or biological product requiring an approved licence or an active investigational new drug application. U.S. Food and Drug Administration — [Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal). *FDA Guidance Document*, 2020. 8. A meta-analysis of the PLACEBO arms of 73 double-blind trials (5,895 patients) quantified what a saline knee injection alone achieves: statistically and clinically significant improvement in pain, function and quality of life at 1, 3 and 6 months, with responder rates exceeding 50% at all three time points, peaking around 4-8 months and declining by 12 months. Placebo response was stronger in trials with more female participants and in more recently published trials. Previtali D, et al. — [Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression.](https://pubmed.ncbi.nlm.nih.gov/41031623/). *EFORT Open Reviews*, 2025. DOI: 10.1530/EOR-2025-0022. 9. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain. McAlindon TE, et al. — [Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/28510679/). *JAMA*, 2017. DOI: 10.1001/jama.2017.5283. ## What could you ask at a real visit? At QC Kinetix, medical providers are the licensed clinic staff who can review your soreness and goals. Ask about regenerative treatments, the clinic's name for non-surgical blood or marrow procedures. Talk to the clinic team: --- Understand the soreness. Know your next step. Plain answers about sore joints, home relief, warning signs and local care drawn from your blood or pelvic marrow. Plain help for understanding joint soreness, care choices and Mesa travel. For this Mesa injection guide, the site is operated by the owners of the QC Kinetix Phoenix-area clinics. © 2026 Mesa Biologic Safety Desk. Educational information, not personal medical advice.